UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacokinetic aspects of l‐deprenyl (selegiline) and its metabolites

Clinical pharmacology and therapeutics, 1994-12, Vol.56 (6), p.742-749

1994

Volltextzugriff (PDF)

Bioavailability of dexmedetomidine after extravascular doses in healthy subjects

British journal of clinical pharmacology, 2003-12, Vol.56 (6), p.691-693

2003

Volltextzugriff (PDF)

Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline

European journal of clinical pharmacology, 2002-07, Vol.58 (4), p.259-263

2002

Volltextzugriff (PDF)

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole

European journal of clinical pharmacology, 2001-04, Vol.57 (1), p.37-42

2001

Volltextzugriff (PDF)

Marked Effect of Liver and Kidney Function on the Pharmacokinetics of Selegiline

Clinical pharmacology and therapeutics, 2005-01, Vol.77 (1), p.54-62

2005

Volltextzugriff (PDF)

Pharmacokinetics and dissolution of two crystalline forms of carbamazepine

International journal of pharmaceutics, 1983-03, Vol.14 (1), p.103-112

1983

Volltextzugriff (PDF)

Inhibition of Platelet Monoamine Oxidase Type B by Selegiline

Journal of clinical pharmacology, 1997-07, Vol.37 (7), p.597-601

1997

Volltextzugriff (PDF)

Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids

British journal of clinical pharmacology, 1999-03, Vol.47 (3), p.249-254

1999

Volltextzugriff (PDF)

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin

Clinical pharmacology and therapeutics, 1998-12, Vol.64 (6), p.648-654

1998

Volltextzugriff (PDF)

Effect of the novel anxiolytic drug deramciclane on cytochrome P 450 2D6 activity as measured by desipramine pharmacokinetics

European journal of clinical pharmacology, 2004-02, Vol.59 (12), p.893-898

2004

Volltextzugriff (PDF)

CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline

European journal of clinical pharmacology, 2001-05, Vol.57 (2), p.137-142

2001

Volltextzugriff (PDF)

Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers

European journal of pharmaceutics and biopharmaceutics, 2004-11, Vol.58 (3), p.689-695

2004

Volltextzugriff (PDF)

Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics

European journal of clinical pharmacology, 2004-02, Vol.59 (12), p.893

2004

Volltextzugriff (PDF)

Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics

European journal of clinical pharmacology, 2004-02, Vol.59 (12), p.893

2004

Volltextzugriff (PDF)

Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone

European journal of clinical pharmacology, 2003-12, Vol.59 (10), p.761-766

2003

Volltextzugriff (PDF)

Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding

Clinical neuropharmacology, 2000, Vol.23 (1), p.22-27

2000

Volltextzugriff (PDF)

Lack of adverse interactions between concomitantly administered selegiline and citalopram

Clinical neuropharmacology, 1997-10, Vol.20 (5), p.419-433

1997

Volltextzugriff (PDF)

Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration

Drugs in R&D, 2003, Vol.4 (6), p.339-345

2003

Volltextzugriff (PDF)

CYP2D6 polymorphism is not crucial for the disposition of selegiline

Clinical pharmacology and therapeutics, 1998-10, Vol.64 (4), p.402-411

1998

Volltextzugriff (PDF)

Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine

Cancer chemotherapy and pharmacology, 2000, Vol.46 (1), p.27-34

2000

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine

Clinical pharmacology and therapeutics, 1992-11, Vol.52 (5), p.537-546

1992

Volltextzugriff (PDF)

Toremifene concentration and multidrug resistance in lung tumors

Cancer chemotherapy and pharmacology, 1996-12, Vol.39 (3), p.212-216

1996

Volltextzugriff (PDF)

Reversal of the Sedative and Sympatholytic Effects of Dexmedetomidine with a Specific α2-Adrenoceptor Antagonist Atipamezole

Anesthesiology (Philadelphia), 1998-09, Vol.89 (3), p.574-584.

1998

Volltextzugriff (PDF)

Influence of age on toremifene pharmacokinetics

Cancer chemotherapy and pharmacology, 1997, Vol.40 (2), p.185-188

1997

Volltextzugriff (PDF)

Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans

Journal of clinical pharmacology, 1997-07, Vol.37 (7), p.602-609

1997

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(153)
Mit Volltextzugriff
(149)

Publikationsform

Sprache

Englisch
(183)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

Science & Technology
(145)
Life Sciences & Biomedicine
(121)
Humans
(94)
Female
(68)
Male
(62)
Biological And Medical Sciences
(59)
Adult
(53)
Medical Sciences
(52)
Middle Aged
(39)
Pharmacology & Pharmacy
(38)
Aged
(28)
Pharmacology. Drug Treatments
(23)
Technology
(19)
Finland - Epidemiology
(18)
Public, Environmental & Occupational Health
(18)
Engineering
(17)
Time Factors
(17)
Toxicology
(17)
Physical Sciences
(16)
Administration, Oral
(15)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacokinetic aspects of l‐deprenyl (selegiline) and its metabolites

Bioavailability of dexmedetomidine after extravascular doses in healthy subjects

Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole

Marked Effect of Liver and Kidney Function on the Pharmacokinetics of Selegiline

Pharmacokinetics and dissolution of two crystalline forms of carbamazepine

Inhibition of Platelet Monoamine Oxidase Type B by Selegiline

Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids

Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin

Effect of the novel anxiolytic drug deramciclane on cytochrome P 450 2D6 activity as measured by desipramine pharmacokinetics

CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline

Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers

Effect of the novel anxiolytic drug deramciclane on cytochrome P450 2D6 activity as measured by desipramine pharmacokinetics

Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics

Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone

Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding

Lack of adverse interactions between concomitantly administered selegiline and citalopram

Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration

CYP2D6 polymorphism is not crucial for the disposition of selegiline

Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine

Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine

Toremifene concentration and multidrug resistance in lung tumors

Reversal of the Sedative and Sympatholytic Effects of Dexmedetomidine with a Specific α2-Adrenoceptor Antagonist Atipamezole

Influence of age on toremifene pharmacokinetics

Desmethylselegiline, a Metabolite of Selegiline, Is an Irreversible Inhibitor of Monoamine Oxidase Type B in Humans

Suchergebnisse filtern